Quantitative clinical glycomics strategies: A guide for selecting the best analysis approach.
Quantitative clinical glycomics strategies: A guide for selecting the best analysis approach.
复制标题
DOI：
10.1002/mas.21688
复制
发表时间：
2022-11
影响因子：
6.6
通讯作者：
Desaire H
中科院分区：
文献类型：
--
作者：
Patabandige MW;Pfeifer LD;Nguyen HT;Desaire H
聚糖将复杂性引入它们所连接的蛋白质。这些修饰在许多疾病的进展过程中变化;因此，它们作为疾病诊断和预后的潜在生物标志物。聚糖的巨大结构多样性使得糖基化分析和定量困难。幸运的是，分析技术的最新进展提供了量化来自复杂生物混合物的低丰度糖肽和聚糖的机会，从而可以识别健康样品和来自疾病状态的样品之间的糖基化差异。了解不同的定量糖组学分析方法的优点和缺点对于选择最佳策略来分析任何给定的临床样品组中的糖基化变化是重要的。为了提供指导选择适当的方法，我们讨论了四种广泛使用的定量糖组学分析平台，包括基于荧光的N-连接聚糖分析和三种不同的基于MS的分析：糖肽的LC-MS分析，MALDI-TOF MS和释放的N-连接聚糖的LC-ESI-MS分析。比较这些方法的优点和缺点，特别是与临床生物标志物研究重要的品质因数相关，包括：初始样品要求、方法的通量、样品制备时间、鉴别的物质数量、方法用于异构体分离和结构表征的实用性、与定量相关的方法相关挑战、重复性、所需的专业知识，以及每次分析的成本。因此，这篇评论提供了独特的指导研究人员奋进进行临床糖组学分析，通过提供现有的分析技术的见解。
Glycans introduce complexity to the proteins to which they are attached. These modifications vary during the progression of many diseases; thus, they serve as potential biomarkers for disease diagnosis and prognosis. The immense structural diversity of glycans makes glycosylation analysis and quantitation difficult. Fortunately, recent advances in analytical techniques provide the opportunity to quantify even low-abundant glycopeptides and glycans derived from complex biological mixtures, allowing for the identification of glycosylation differences between healthy samples and those derived from disease states. Understanding the strengths and weaknesses of different quantitative glycomics analysis methods is important for selecting the best strategy to analyze glycosylation changes in any given set of clinical samples. To provide guidance towards selecting the proper approach, we discuss four widely used quantitative glycomics analysis platforms, including fluorescence-based analysis of released N-linked glycans and three different varieties of MS-based analysis: LC-MS analysis of glycopeptides, MALDI-TOF MS, and LC-ESI-MS analysis of released N-linked glycans. These methods’ strengths and weaknesses are compared, particularly associated with the figures of merit that are important for clinical biomarker studies, including: the initial sample requirements, the methods’ throughput, sample preparation time, the number of species identified, the methods’ utility for isomer separation and structural characterization, method-related challenges associated with quantitation, repeatability, the expertise required, and the cost for each analysis. This review, therefore, provides unique guidance to researchers who endeavor to undertake a clinical glycomics analysis by offering insights on the available analysis technologies.
登录
查看更多内容
影响因子：
5.4
作者：
Go, Eden P.;Herschhorn, Alon;Desaire, Heather
通讯作者：
Desaire, Heather
影响因子：
7.4
作者：
Chen B;Zhong X;Feng Y;Snovida S;Xu M;Rogers J;Li L
通讯作者：
Li L
DOI：
10.1083/jcb.200808124
发表时间：
2009-03-23
期刊：
The Journal of cell biology
影响因子：
--
作者：
Glozman R;Okiyoneda T;Mulvihill CM;Rini JM;Barriere H;Lukacs GL
通讯作者：
Lukacs GL
影响因子：
9.3
作者：
Chen, Jie;Li, Xueli;He, Miao
通讯作者：
He, Miao
影响因子：
4.3
作者：
Alvarez-Manilla, Gerardo;Warren, Nicole Lynn;Orlando, Ron
通讯作者：
Orlando, Ron